Q-omics provides the consensus-scored C1QTNF7 profile across patient tissues and cancer cell-line models. C1QTNF7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C1QTNF7 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, C1QTNF7 RNA expression shows 22,587 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, COAD, and BRCA as cancer lineages where C1QTNF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QTNF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QTNF7 survival associations across molecular data types. C1QTNF7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QTNF7 RNA expression–survival associations across cancer types. High C1QTNF7 expression shows unfavorable associations in KIRP and ACC, but favorable associations in UCEC, KIRC, HNSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C1QTNF7 RNA expression.
This table summarizes C1QTNF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C1QTNF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QTNF7 shows lower tumor expression in COAD, KIRC, BLCA, KICH, KIRP and HNSC. The COAD box plot shows higher C1QTNF7 RNA expression in normal versus tumor tissue (log2 FC = −1.686, t-test p < 0.001).
This table shows molecular features associated with C1QTNF7 in patient tissues and cancer cell lines. In patient samples, C1QTNF7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QTNF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
